Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2020 Dec 10;16(12):e1009260. doi: 10.1371/journal.pgen.1009260

TDP-43 mutations link Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage

Marta Giannini 1,2,3,#, Aleix Bayona-Feliu 3,4,#, Daisy Sproviero 1,#, Sonia I Barroso 3, Cristina Cereda 1,*, Andrés Aguilera 3,4,*
Editor: Dmitry A Gordenin5
PMCID: PMC7755276  PMID: 33301444

Abstract

TDP-43 is a DNA and RNA binding protein involved in RNA processing and with structural resemblance to heterogeneous ribonucleoproteins (hnRNPs), whose depletion sensitizes neurons to double strand DNA breaks (DSBs). Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder, in which 97% of patients are familial and sporadic cases associated with TDP-43 proteinopathies and conditions clearing TDP-43 from the nucleus, but we know little about the molecular basis of the disease. After showing with the non-neuronal model of HeLa cells that TDP-43 depletion increases R loops and associated genome instability, we prove that mislocalization of mutated TDP-43 (A382T) in transfected neuronal SH-SY5Y and lymphoblastoid cell lines (LCLs) from an ALS patient cause R-loop accumulation, R loop-dependent increased DSBs and Fanconi Anemia repair centers. These results uncover a new role of TDP-43 in the control of co-transcriptional R loops and the maintenance of genome integrity by preventing harmful R-loop accumulation. Our findings thus link TDP-43 pathology to increased R loops and R loop-mediated DNA damage opening the possibility that R-loop modulation in TDP-43-defective cells might help develop ALS therapies.

Authors’ summary

Amyotrophic Lateral Sclerosis (ALS) is an adult onset, progressive neurodegenerative disease, caused by the selective loss of upper and lower motor neurons in the cerebral cortex, brainstem and spinal cord. The nuclear TDP-43 RNA binding protein, is encoded by a major gene for ALS susceptibility whose mutations are found in 3% of familial and 2% of sporadic ALS cases. Thanks to its ability to recognize DNA and RNA, TDP-43 is involved in different steps of mRNA metabolism and in several mechanisms of genome integrity. This, together with the fact that R loops or DNA-RNA hybrids are a common source of genome instability, prompted us to investigate whether TDP-43 deficiency has any role in R loop homeostasis that could explain previously described DNA damage response defects of ALS cells. We show that TDP-43 plays a role in preventing R loop-accumulation and associated genome instability in neuronal and non-neuronal cells, as well as in patient cell lines. Thus, our study opens the possibility that R loop-modulation in TDP-43-defective cells might help develop ALS therapies.

Introduction

TDP-43 is a nuclear RNA binding protein (RBP) with a repressor role of HIV-1 transcription. It binds to the trans-active response element DNA sequence of the viral genome [1, 2]. Like other hnRNP proteins, TDP-43 binds to nascent pre-mRNA molecules when they are released from the RNA Polymerase II (RNApol II) and regulates RNA maturation either through sequential interactions with or in collaboration/antagonism with specific RNA binding factors [3]. TDP-43 is also involved in the regulation of non-coding RNAs like miRNAs and lncRNAs [4, 5]. Thanks to its ability to recognize single-stranded DNA (ssDNA) or single-stranded RNA (ssRNA) with a preferential binding to (UG)n-enriched sequences [6], TDP-43 is involved in different steps of mRNA metabolism and in several mechanisms of genome integrity [7], consistent with the idea that RNA metabolism and DNA damage response (DDR) may be functionally interconnected [8].

Mutations in TDP-43 are associated with sporadic and familial cases of Amyotrophic Lateral Sclerosis (ALS), an adult onset, progressive neurodegenerative disease, caused by the selective loss of upper and lower motor neurons in the cerebral cortex, brainstem and spinal cord [9, 10]. TARDBP is a major pathological gene for the ALS susceptibility and their mutations are found in 3% of familial and 2% of sporadic ALS cases [11, 12]. Particularly, homozygous p.A382T TARDBP variation (A382T TDP-43) is one of the most common missense mutation in familial patients. A382T TDP-43 accumulation in the cytoplasm can reduce its physiological nuclear function, such as transcription regulation, mRNA splicing and transport [1315] and miRNAs biogenesis [5, 9]. Subsequent to this, the formation of oligomers and aggregates of TDP-43 in the cytoplasm may recruit native TDP-43 or other interactors proteins [16], constituting a gain of toxic function associated with neurodegeneration [17]. TDP-43 aggregates are identified as a major component of the ubiquitinated neuronal cytoplasmic inclusions deposited in spinal motor neurons both in familiar and sporadic ALS patients [18].

In addition to transcriptional autoregulation, TDP-43 can be cleaved into smaller C-terminal fragments before being enzymatically degraded to maintain its physiological levels [9, 19] by a range of cysteine proteases, including caspases and calpains. Moreover, lines of evidence suggest that these CTFs can be produced via translation of an alternative transcript which is upregulated in ALS [20]. Recent studies proved that increased cytosolic sequestration of the poly-ubiquitinated and aggregated forms of mutant TDP-43 correlates with higher levels of DNA strand breaks, activation of DDR factors such as phospho-ataxia-telangiectasia mutated (ATM), phospho-53BP1, γH2AX in SH-SY5Y lines expressing wild-type (WT) or Q331K-mutant TDP-43 [21]. TDP-43 depletion leads to increased sensitivity to various forms of DNA damage and mutation in the C-terminus glycine-rich low-complexity region (LC domain) associates with the loss of its nuclear function [22]. In addition, TDP-43 colocalizes with active RNA polymerase II at sites of DNA damage along with the DDR protein, BRCA1, participating in the prevention and/or repair of R loop-associated DNA damage [23].

Evidence indicate that a major source of spontaneous DNA damage comes from the accumulation of R-loops, consisting in DNA-RNA hybrids and a displaced single strand DNA (ssDNA) [8]. Non-physiological R loops occur as unscheduled events formed co-transcriptionally that can compromise genome integrity. Increasing evidence [16, 24] has highlighted a common association of increased R-loops with a variety of genetic diseases, including neurodegenerative disorders [25]. R-loop formation is enhanced in genomic regions containing highly repetitive DNA, which could facilitate the thermodynamic stabilization of RNA-DNA hybrids [26, 27] and in cells mutated in genes encoding factors controlling R-loop homeostasis. Such factors are generally related to RNA processing and export or have DNA-RNA unwinding (helicase) or hybrid-specific ribonuclease (RNase H) activities [28, 29]. However, a crucial role in prevention of R-loop formation is also played by the DDR. It is particularly notorious the role of BRCA2 and BRCA1 DSB repair factors or the Fanconi Anemia pathway (FA), especially FANCD2, involved in the repair of the inter-strand crosslinks (ICLs) and replication fork blockages [30, 31]. Deficiency on any of these factors lead to harmful R-loop accumulation in human cells [8].

All this, together with the fact that a number of neurodegenerative diseases highlight a particular sensitivity of the nervous system and motor neurons are associated with deficiencies in RNA metabolism and DDR, prompted us to investigate whether TDP-43 deficiency, as found in ALS cells, have a role in R-loop homeostasis that could explain previously described DDR defects of ALS cells. We show that TDP-43 plays a role in preventing R-loop accumulation and R loop-mediated DNA breaks in neuronal and non-neuronal cells and in patient cell lines, thus opening the possibility that R-loop modulation in TDP-43-defective cells might help develop ALS therapies.

Results

TDP-43 depletion causes R loops, DNA damage and FANCD2 repair centers in HeLa cells

A key regulatory role of TDP-43 in essential metabolic processes was previously suggested since silencing of TDP-43 in HeLa cells lead in dysmorphic nuclear shape, misregulation of the cell cycle, apoptosis, increase in cyclin-dependent kinase 6 (Cdk6) transcript and protein levels [32]. As a major readout associated with RNA transcription metabolic defects, we analyzed accumulation of nuclear DNA-RNA hybrids in TDP-43 depleted HeLa cells (siTDP-43 HeLa cells) as a reference cell line commonly used in R loop and genome integrity studies.

Genomic DNA-RNA hybrids in siTDP-43 HeLa cells were first assessed by immunofluorescence microscopy (IF) using the anti-DNA-RNA hybrid S9.6 antibody, and determining the levels of the S9.6 signal in the nucleoplasm after subtracting the nucleolar contribution [33, 34]. As controls we used HeLa cells transiently transfected with a mock control vector expressing GFP (siC) or overexpressing the RNaseH1 enzyme, which specifically degrades the RNA moiety of hybrids. A slight but significant increase of R loops was observed in siTDP-43 HeLa cells, in which TDP-43 protein levels were reduced 75% (S1A Fig), in comparison to the siC (Fig 1A). Efficient RNaseH1 overexpression from the pEGFP-M27 plasmid, as confirmed by IF (S1B Fig), reduced significantly the S9.6 signal, confirming that the signal detected corresponded to R-loops (Fig 1A). A comparative analysis of the S9.6 signal intensity obtained for depletion of other cellular factors that protect cells from R loops in HeLa cells shows that the signal increase after TDP-43 depletion was similar to that obtained by depletion of other factors such as THOC1, UAP56, SETX, AQR, DDX23 mRNP processing factors (S1C Fig).

Fig 1. R-loops accumulation in siTDP-43 HeLa.

Fig 1

A) siC and siTDP-43 HeLa immunostaining with antiS9.6 antibody and anti-nucleolin antibody. The graph shows the median of the S9.6 intensity per nucleus after nucleolar signal removal. Around 300 cells from three independent experiments were considered. Scale bar: 25μm. ***, P < 0,0002; **, P < 0,001 (Mann-Whitney U test, two-tailed). B) DRIP-qPCR using the anti S9.6 antibody at RPL13A, APOE, WDR90, EGR1 and MIB2 are shown in siC HeLa and siTDP-43 HeLa. Pre-immunoprecipitated samples were untreated (-) or treated (+) with RNaseH, as indicated. Data represent mean ± SEM from three independent experiments. *, P <0,05, **, P < 0,01, ***, P < 0,001 (Upaired t test, one-tailed). In all cases, when no asterisk is shown indicates that is not significant.

Next, we determined R-loop accumulation by the more accurate method of DNA-RNA immunoprecipitation (DRIP)-qPCR, based specifically on the purification of genomic DNA-RNA hybrids of different sizes. In this case the S9.6 signal was determined for genes expressed at different levels such as APOE, RPL13A, WDR90, EGR1 and MIB2, which have been previously validated for the detection of R loops [31, 33, 35], and the poorly expressed SNRPN gene used as negative control [35, 36]. We detected accumulation of DNA-RNA hybrids in the analysed genes in siTDP-43 HeLa cells compared to the siC HeLa cells, obtaining a significative increase on all genes tested (Fig 1B), whereas the SNRPN negative control did not show R loop accumulation (S1D Fig), further supporting the validity of our DRIP-qPCR methodology for R loop detection. Importantly, RNaseH treatment induced a dramatic signal decrease confirming that signals were R-loop specific (Fig 1B).

Then, we investigated the functional impact of nuclear DNA-RNA hybrid enrichment on DDR, given that hybrids have been shown to enhance transcription-replication conflicts [37]. As can be seen in Fig 2A, γH2AX foci, as determined by IF, were significantly increased in siTDP-43 compared to siC HeLa cells. γH2AX foci significantly decreased after RNaseH1 overexpression, indicating that the damage caused by TDP-43 depletion is R-loop mediated. It has been shown that the Fanconi Anemia (FA) repair pathway is a critical pathway to resolve R loop-mediated DNA breaks as the result of transcription-replication collisions and that the FA factors work at the collisions [30, 31, 3840]. Therefore, we tested whether the damage generated by TDP-43 depletion was signaled by the FA pathway, for which we used the FANCD2 component [38]. As it can be seen in Fig 2B, FANCD2 foci were significantly increased in siTDP-43 HeLa cells compared to the siC control. Importantly, this increase was reduced by RNaseH1 overexpression, proving that TDP-43 depletion is responsible for an accumulation of the Fanconi Anemia repair factor caused by R-loop accumulation. The result is consistent with the idea that FANCD2 accumulates at R loop-containing sites at which the replication fork is blocked, similarly to inactivation of other RNA metabolic factors that lead to R-loop accumulation [38, 41].

Fig 2. TDP-43 associates with FANCD2 and affects genome integrity in siTDP-43 HeLa.

Fig 2

A) Detection of γH2AX foci by IF in siC and siTDP-43 HeLa. The histogram shows the quantification of the relative amount of cells in percentage containing >10 γH2AX foci in each case. More than 100 cells were counted in each of the three experiments. Data represent mean ± SEM from three independent experiments. Scale bar: 25μm. **, P<0,01 and *, P< 0,05 (Upaired t test, two-tailed). B) Detection of FANCD2 foci by IF in siC and siTDP-43 HeLa. The histograms show the quantification of the relative amount of cells in percentage containing >10 FANCD2 foci in each case. Details as in Fig 2A. Scale bar: 25μm. **, P<0,01 and *, P< 0,05 (Upaired t test, two-tailed). In all cases, when no asterisk is shown indicates that is not significant.

Genome-wide co-localization of TDP-43 at expressed genes

Our results show that TDP43 depletion causes R loop-accumulation, R loop-dependent DNA damage and accumulation of the transcription-replication collision-associated FANCD2 repair foci similar to depletion of other mRNP processing factors that function co-transcriptionally together with RNA polymerase II (RNAPII). Indeed, genome-wide ChIP-seq data obtained in K562 erythroblastoma cells (ENCODE Project; ENCSR033VAZ entry) reveals that TDP-43 colocalizes with expressed genes defined by RNA-seq (Fig 3A). 6011 out of 6245 of genes recruiting TDP-43 correspond to actively expressed genes (Fig 3B). Consistently, TDP-43 occupancy is significantly higher in expressed genes compared to genes with low or non-detectable expression, with a preference towards the 5’ end of the genes (Fig 3C and 3D). Interestingly, analysis of the genes reported to be prone to accumulate R loops in K562 cells [42] reveals that 4809 of the 6245 genes are enriched in TDP-43. These results support that the TDP-43 RBP is present at expressed genes that are prone to accumulate R loops, where it might participate in mRNP biogenesis, similarly as proposed for other co-transcriptional RNA binding factors [8]. A remaining question is which specific role TDP-43 may play during transcription of those genes.

Fig 3. TDP-43 co-localizes genome-wide with expressed R loop-prone genes.

Fig 3

A) Screnshoots of genome windows showing co-occurrence between TDP43 (red), DRIPc-seq (green), untreated (dark blue) and RNH-treated (light blue) DRIP-seq and RNA-seq (yellow) data. Genome location is indicated in the top left corner and scale in the top right. Coverage scale indicated in the top left of each track. Biological replicates are also indicated (R1, R2). B) Venn diagram showing correlation between genes bind by TDP-43 (TDP43; red circle), genes forming R loops (DRIPc-seq; green) and expressed genes (RNA-seq; yellow). Numbers refer to genes co-occurring between conditions. C) TDP-43 ChIP-seq average coverage (log10) across silent (-) and expressed (+) genes. ****, P < 0,0001 (Mann-Whitney U test, two-tailed). D) Metagene analysis showing TDP-43 ChIP-seq coverage (red line) along gene body (+/- 2kb) of silent (-) and expressed (+) genes. Mean coverage is plotted in the upper panel and heatmap intensities for the entire gene population is shown below. Scale is also indicated.

Cytoplasmic mislocalisation of mutated TDP-43 causes R-loop accumulation and leads to activation of the DDR and the Fanconi Anemia pathway

In ALS patients harboring TDP-43 mutations, TDP-43 mislocalizes from the nucleus to the cytoplasm in detergent-resistant aggregated forms either full-length (43 KDa) and fragmented forms (35KDa, 25KDa), which can be ubiquitinated and hyperphosphorylated [43]. We hypothesized that TDP-43 mislocalization due to missense mutations could have an impact on R-loop accumulation and DNA damage in ALS disease. For this we moved our studies to the SH-SY5Y neuroblast-like cells usually used as in vitro models of neuronal function and differentiation and to assay ALS related mutations. To determine TDP-43 cellular localization, we performed IF microscopy in basal SH-SY5Y, SH-TDP+ (overexpressing a GFP-tagged TDP-43 WT form), SH-TDP382 (expressing the GFP-tagged p.A382T TDP-43 mutant form) and SH-TDP294 (expressing the GFP-tagged p.G294V TDP-43 mutant form) cells using an anti-TDP-43 or anti-GFP antibody, able to detect the wild-type nuclear protein and the cytoplasmic full length and fragmented forms. In all cases, TDP-43 overexpression levels, as determined by Western were similar (S2A Fig), excluding the possibility that a potential different phenotype could be attributed to different TDP-43 levels rather than the dysfunction caused by the mutation itself. Western blot analysis of nuclear and cytoplasmic fractionation showed an increase level of GFP-fused proteins in the cytoplasm of SH-TDP+ and SH-TDP382, reducing the total nuclear fraction, including endogenous TDP-43 and GFP-fused, with respect to the cytoplasmic fraction (S2B Fig). In the case of SH-TDP294, the ratio between nuclear and non-nuclear signal did not show the same tendency, raising the possibility that protein dysfunction can be causative of the phenotype. However, in all cases, SH-TDP+, SH-TDP382 and SH-TDP294 the cytoplasmic fraction of the GFP-overexpressed protein was clearly higher compared to the SH-SY5Y control, consistent with a cytoplasmic mislocalization. From now we focused our study in the A382T mutant.

We confirmed by flow cytometry and IF that overexpression of both TDP+ and TDP382 occurred at similar levels (S2C and S2D Fig). In addition, in SH-TDP+, the RBP was localized preferentially in the perinuclear area compared to non-transfected SH-SY5Y cells, in which localization was predominantly nucleoplasmic. TDP-43 nuclear localization was significantly decreased in SH-TDP382 cells compared both to non-transfected SH-SY5Y and SH-TDP+ (S2E Fig). These changes could not be attributed to differences in nuclear area as these did not show any significant difference (S2F Fig), confirming that the A382T mutation is linked to TDP-43 cytoplasmic mislocalization with formation of inclusions or aggregates as previously reported for this and other mutations [4446]. Results were the same when using the anti-TDP43 or anti-GFP antibodies.

Next, we tested whether mislocatization of TDP-43 could impact onto genomic integrity and R-loop accumulation in these cells. We first assayed whether overexpression of wild-type TDP-43 and mutated and mislocalized TDP-43 affected R-loop accumulation. Since both mutated and overexpressed TDP-43 may affect its physiological role in miRNA biogenesis, we added in this case an additional treatment with RNaseIII, which degrades specifically dsRNAs, to counteract the reported ability of S9.6 to detect dsRNAs [47, 48]. A significant increase of nucleolar S9.6 intensity was detected both in SH-TDP+, SH-TDP382 and SH-TDP294 cells compared to SH-SY5Y (Fig 4A and S3A Fig). Furthermore, RNaseH1 overexpression, as confirmed by IF (S3B Fig) caused nuclear S9.6 signal decrease in both SH-TDP382 and SH-TDP294 cells, but not in SH-TDP+ cells. Therefore, we conclude that ALS TDP-43 mutations also cause R-loop accumulation. From now on we focused our study on the TDP-43 A382T mutant protein as a representative mutant protein linked to ALS.

Fig 4. R-loops accumulation in SHSY-TDP382 and SHSY-TDP294 overexpressing SH-SY5Y cells.

Fig 4

A) IF using anti S9.6 antibody and anti-nucleolin antibody of SH-SY5Y, SH-TDP+, SH-TDP382 and SH-TDP294. The graph shows the quantification of S9.6 nuclear signal. Details as in Fig 1A. ****, P < 0.0001 (Mann-Whitney U test, two-tailed). B) DRIP-qPCR using S9.6 antibody, at RPL13A,WDR90 and EGR1 genes in basal SH-SY5Y, SH-TDP+, SH-TDP382 and SH-TDP294. Details as in Fig 1B. *, P < 0,05; **, P < 0,01; *** P < 0,001; ****, P < 0,0001 (Unpaired t test, one-tailed). In all cases, when no asterisk is shown indicates that is not significant.

We performed DRIP-qPCR in the neuroblastoma cell lines in previously validated genes for R loop detection [33, 35, 36], to confirm the results involving TDP-43 role in preventing R-loop accumulation in human cells. Consistent with IF results a statistically significant increase in R loops was detected by DRIP-qPCR in RPL13A, WDR90 and EGR1 genes in SH-TDP382 cells, even though not for APOE likely due to an unknown cell type-specific effect (Fig 4B). The levels were minimal for the SNRPN negative control (S3C Fig). RNaseH treatment dramatically decreased the levels of the signal in all cases, confirming that the signal detected was specific for nuclear DNA-RNA hybrids. Results were thus consistent with those obtained in TDP-43-depleted HeLa cells. Interestingly, an increase in the immunoprecipitated material was also detected in some genes in SH-TDP+ cells (Fig 4B). In this sense, it is worth noting that overexpression of wild-type TDP-43 has been reported to be detrimental to cells [49], and also led to a minor but significant decrease in nuclear TDP-43 abundance (S2B Fig). This could explain the minor but significant R-loop increase observed by DRIP at some genes in SH-TDP+, consistent with the high R-loop levels correlating with a low nuclear TDP-43 content, as is the case of SH-TDP382 cells.

To test whether R-loop accumulation observed in SH-TDP382 cell lines causes DNA damage we determined the levels γH2AX foci by IF microscopy and their dependence of R-loops by testing whether RNaseH1 overexpression reduced them. As can be seen in Fig 5A, γH2AX foci were significantly increased in SH-TDP382 cells whereas this was not the case in SH-TDP+ cells expressing the wild-type form of TDP-43. The increase in damage was suppressed by RNaseH1 overexpression, indicating that DNA break accumulation caused by mutant TDP43 was mediated by DNA-RNA hybrids.

Fig 5. TDP-43 associates with FANCD2 and affects genome integrity in stable transfected SHSY-TDP382-.

Fig 5

A) Detection of γH2AX foci, by IF in SH-SY5Y, SH-TDP+ and SH-TDP382. The histogram shows the quantification of the relative amount of cells in percentage containing >10 γH2AX foci in each case. Details as in Fig 2A. Scale bar: 25μm. *, P < 0,05 (Upaired t test, two-tailed). B) Detection of FANCD2 foci by IF in SH-SY5Y, SH-TDP+ and SH-TDP382. The graph shows the quantification of the relative amount of cells in percentage containing >10 FANCD2 foci in each case. Details as in Fig 2A. Scale bar: 25μm. *, P < 0,05 (Upaired t test, two-tailed). In all cases, when no asterisk is shown indicates that is not significant.

Next, we tested whether the origin of such DNA damage was due to an increase in transcription-replication collisions enhanced by R-loops. We determined the levels of FANCD2 foci as previously reported. Notably, FANCD2 foci were significantly increased in SHSY-TDP382 mutant cells compared to SHSY-TDP+ and this increase was reduced by RNaseH1 overexpression (Fig 5B). Therefore, the ALS pathogenic TDP-43 mutation in the analysed neuronal model leads to a comparable functional effect to that observed in silenced HeLa cells. The pathogenic TDP-43 mutation causes an increase in DNA breaks derived from R-loop accumulation that promotes transcription-replication collisions that are processed by the FA pathway, as reported for other cases of recombinogenic R-loops [30, 31, 3840].

Accumulation of R-loops in p.A382T TDP-43 mutated lymphoblastoid cell lines

Next, we used lymphoblastoid cell lines (LCLs) that derive from a TDP-43 mutated patient carrying p.A382T mutation (LCL-TDP382), a sporadic ALS patient (LCL-SALS) and a healthy control (LCL-CTL) (see Materials and methods) to confirm the role of TDP-43 in R-loops removal in ALS. We performed IF microscopy for S9.6 and TDP-43 in the three cell lines mentioned with two fixation methods, methanol (Fig 6A) and paraformaldehyde (S4A Fig). R-loop quantification of the IFs confirmed a significant R-loop accumulation in LCL-TDP382 cells using both fixation methods. Concomitantly, both fixation methods guaranteed a decreased detection level of TDP-43 signal in the nucleus of LCL-TDP382 in comparison to LCL-CTL and LCL-SALS was also detected (Fig 6A and S4A Fig). This is in accordance with the mislocalisation of the mutated protein in the cellular cytoplasm, causing the loss of its nuclear physiological function [50]. Again, all these changes in nuclear content could not be attributed to changes in nuclear area as this remains the same (S4B and S4C Fig). Moreover, there is a colocalization of S9.6 signal with TDP-43 in the perinuclear area of LCL-TDP382 cells in comparison to LCL-CTL and LCL-SALS. R-loop quantification was also determined in LCLs by flow cytometry, in which case the analysis reported an increased positivity of S9.6 intensity in the orange peak associated with LCL-TDP382, in comparison to the blue peak associated with LCL-CTL (Fig 6B). The positive signal in LCL-TDP382 represented by the orange peak was clearly suppressed by RNase H treatment in the same sample detected as green peak, confirming that the detected signal corresponds to DNA-RNA hybrids (Fig 6B).

Fig 6. R-loops accumulate in p.A382T TDP-43 mutated LCLs.

Fig 6

A) IF of LCL-CTL, LCL-TDP382, LCL-SALS using an anti-TDP-43 antibody and an anti-S9.6 antibody after methanol fixation. The scatter plots show the increase of S9.6 signal intensity and the decrease in TDP-43 nuclear content in SH-TDP382. Median values are indicated. Scale bar: 25μm. *, P< 0,05 (Mann-Whitney U test, two-tailed). When no asterisk is shown indicates that is not significant. B) Flow cytometry plot reports the amount of R-loops in LCLs (blue) in comparison to LCL-TDP382 (orange) and LCL-SALS (blue). The RNaseH action on LCL-TDP382 decreases the presence of R-loops signal (orange peak vs green peak). Histogram shows S9.6 mean fluorescence of LCL-CTL, LCL-TDP382, LCL-SALS in presence (+) and in absence (-) of RNaseH. The value represented is the mean ± SEM of three biological experiments. ANOVA, Newman-Keuls Multiple Comparison Test, *P <0,05. When no asterisk is shown indicates that is not significant. C) Model showing the link between TDP-43 and R loop metabolism. Functional TDP43 activity in the nucleus protects genome integrity by preventing R-loop accumulation. However, TDP-43 nuclear dysfunctions results in R loop-dependent DNA damage that eventually might lead to genome instability that could aggravate ALS phenotype.

Finally, we investigated the possibility that TDP-43 could have a role on DNA-RNA hybrid-enriched chromatin, in which case we should expect some kind of physical association. Therefore, we wondered whether TDP-43 and genomic DNA-RNA hybrids colocalize by performing a co-immunoprecipitation (coIP) in chromatin (Chr) fractions from the three cell lines (S5A Fig). At the same time, we extracted whole lysate (WL) fractions from the same samples as control (S5B Fig). In the Chr fraction, co-immunoprecipitation could be observed with the S9.6 antibody. In LCL-TDP382, the TDP-43 mutant protein showed lower levels of co-IP, while in the WL fraction of the same sample the co-IP signal was higher than the CTRL-LCLs (S5B Fig), which suggests that the mutant full length TDP-43 was not able to interact with R loop-enriched chromatin due to its sequestration at the cytosolic compartment in the cell [50], as seen before (Fig 6A and S4A Fig). Interestingly, the truncated TDP-35 form detected in Chr fraction of LCLs show high levels of S9.6 co-IP in the WL fraction of LCL-TDP382 in comparison with control LCL-CTL and LCL-SALS. This specific C-terminal mutation may predispose TDP-43 to fragmentation into CTFs, which as reported in literature are transported out of the nucleus and accumulated into complexes with RNA transcripts [49].

Discussion

Mislocalization of TDP-43 causes a gain of neurotoxic function characteristic of the neurodegeneration process in ALS patients [51]. Moreover, TDP-43 aggregation induced by double-site mutations and TDP-43 knockdown have a common set of differentially expressed proteins, behaving in a similar way [52]. Here we show that mislocalization of mutated TDP-43 can sequester full length TDP-43 form in cytoplasmic inclusions preventing its physiological nuclear function. Importantly, this function is related to R-loop homeostasis. Nuclear depletion of TDP-43, as achieved by either mislocalization to the cytoplasm or siRNA depletion in different cell types, causes a significant increase in harmful R-loops that leads to DNA breaks and FANCD2 foci. The results suggest that the TDP-43 RNA-binding protein has a key role in preventing R-loop accumulation as a safeguard of genome integrity.

Silencing TDP-43 by siRNA in HeLa cells led to a significative increase of R-loop signal by S9.6 IF compared to the siC control. This was confirmed by reversion of signal in case of RNaseH1 overexpression. DRIP-qPCR revealed an important R-loop presence on 5 protein-encoding genes tested. These include RPL13A ribosomal protein gene, whose deficiency could lead to alteration of protein homeostasis and RNA metabolism [53]. In this sense, it is worth noting that TDP-43 interacting protein networks have been shown to include RPL13A [54] and that both C9orf72 mut ALS patients’ derived iPSCs and TDP-43-EGFP overexpressing iPSCs presented a set of commonly destabilized RNAs involved in the ribosomal pathway [55]. However, there is no evidence that these features have any relation to R loop accumulation at RPL13A; indeed, it is a phenomenon observed in non-ribosomal protein genes also (Fig 1).

The absence of nuclear TDP-43 affects the DDR, consistent with previous reports [23]. We showed that siTDP-43 HeLa cells had a significative increase of DSBs as determined by γH2AX foci. Importantly, this DSB increase was R loop-dependent, as it could be fully reverted by RNaseH1 overexpression, and it was accompanied by an accumulation of FANCD2 foci that was also R loop-dependent. The result indicates that TDP-43 prevents the co-transcriptional accumulation of harmful R-loops that promote transcription-replication conflicts that have to be resolved by the FA pathway, consistent with the previously reported role for the FA pathway [37]. These results are particularly meaningful in the context of the putative role of TDP-43 in nuclear RNA processing, yet to be properly defined. It has been well-established that depletion of other factors involved in nuclear RNA metabolism such as the THO complex, UAP56, AQR, DDX23 or SRSF1 causes similar phenotypes as those described here for TDP43 mutations [8]. They all cause R loop accumulation and R loop-dependent genome instability that in cases like THO- and UAP56-depleted cells have been shown to correlate with an increase in FANCD2 foci and transcription-replication conflicts [38, 42]. Indeed, a very recent report that came out while ours was under review shows by DNA combing that siTDP43 cells undergo replication stress [56], consistent with our view. As it happens with those other RBP factors, genome-wide analysis of TDP-43 occupancy correlates with transcriptionally active genes, in which most of R loops accumulate (Fig 3). As shown by other mRNA processing factors, a paradigm of which is the THO complex, we propose that it is the suboptimal action of TDP-43 as an RBP during transcription what is linked to the appearance of R loops (Fig 6C). However, further research is required to completely understand how RBPs and a number of DDX proteins protect from R loops.

Notably, our assay of the impact of the TDP-43 pathogenic ALS mutation and overexpression in a neuroblastoma cell line, SH-SY5Y, revealed that the pathogenic A382T and G294V mutations in SH-SY5Y cells also affected the TDP-43 role controlling R-loop homeostasis, leading to a higher detection of genomic RNA-DNA hybrids, as detected by IF and DRIP-qPCR. As expected, DSBs and replication blockage detected by γH2AX and FANCD2 foci, respectively, were also increased in an R loop-dependent manner.

The effect of TDP-43 deficiency in R-loop homeostasis could be related to the accumulation of aberrant transcripts and hybrids that are trapped in persistent RNA-processing foci present in the cytoplasmic compartment of cell previously reported [57]. Our analysis of ALS patient-derived LCLs as a valid cellular model to study the disease that carries typical features of degenerating MNs in ALS (i.e. protein aggregation, mitochondrial disfunction etc.) [46], also revealed an increased level of nuclear RNA-DNA hybrids in LCL-TDP382 as well as co-localization of S9.6 antibody with a fraction of TDP-43 in the perinuclear area. It is possible that either sequestering of the misfolded and mutated form of TDP-43 in inclusions could cause a loss of its nuclear function or the formation of TDP-43 aggregates in the cytoplasm could recruit native TDP-43 or other interactor proteins constituting a gain of toxic function [58]. The detection of higher S9.6 signal in both in LCL-SALS and of LCL-TDP382 underlines that R-loops may be a general condition in ALS, potentially improving RNA metabolism dysregulation and neurotoxicity that appear to be major contributors to the pathogenesis of this neurodegenerative disease.

It is worth noticing that RNAse III treatment was required to detect RNH-sensitive S9.6 reactivities (Fig 4A). Knowing that S9.6 can also detect dsRNAs [47, 48] this result indicates that TDP-43 overexpression also leads to an accumulation of dsRNA molecules. Interestingly, TDP-43 has been reported to co-localize with Dicer and Ago2, but their interaction is inhibited by aggregates formation in response to cellular stressors or also by overexpression of human TDP-43 [58]. There is no evidence that overexpression and mutation of TDP-43 lead to double hairpin pre-miRNA accumulation in neuronal models, so it is formally possible that dsRNA accumulation observed in SH-SY5Y overexpressing TDP-43 could be associated to inhibition of Dicer processing function responsible for the loss of maturation of pre-miRNAs, presented as dsRNA hairpin structures in mature miRNAs. However, it may also be possible that excess of RBPs would prevent normal RNA metabolism by excess of cellular RBPs that would bind to any RNA molecule having secondary structure segments. A negative impact of RBP overexpression on RNA metabolism has been reported in other cases [59]. These are possibilities to explore in the future.

The chromatin fraction of TDP382 mutated LCLs showed a weaker association between TDP-43 and the S9.6 signal not observed in whole cell extracts, consistent with a lower TDP-43 presence in the nucleus. This decrease was not either observed in cells from a sporadic ALS patient (Fig 6). It is known that in ALS pathological conditions TDP-43 can generate CTFs such as 35 kDa fragments both upon cleavage by caspases at intrinsic caspase cleavage sites [11], both by via translation of upregulated alternative transcript [20]. Due to the lack of nuclear localization signal (NLS), TDP-35 CTFs mislocalize to the cytoplasm, where may associate with RNA forming cytoplasmic inclusions [60]. Indeed, the biochemical analysis suggests that TDP-35 facilitates aggregate assembly promoting inclusion formation [61] and might transport different types of RNA structures. TDP-35 can also recruit full-length TDP-43 to cytoplasmic deposition from functionally nuclear localization [62] and TDP-43 continuously shuttles between nucleus and cytoplasm in a transcription-dependent manner [63]. The higher TDP-35-S9.6 co-IP in the WL fraction of LCL-TDP382 compared to the other LCLs likely may reflect inclusions formed by dsRNAs.

It is becoming clear that impaired RNA regulation and processing is a central feature in ALS pathogenesis. Our study, reinforces the need of understanding the specific role of ALS in RNA metabolism, and in particular in cells defective in the TDP-43 RBP, beyond its effect on the formation of RNA inclusion bodies in the cytoplasm. Even though this is a common read-out of ALS, our study showing an increase in genomic R-loops and DNA damage and Fanconi Anemia foci, expected for obstacles blocking replication, suggests that an important cause of the disease may be linked to impairment of nuclear RNA biogenesis and impact on DDR (Fig 6C). The application of RNA-based therapies to modulation of gene and subsequent protein expression is an attractive therapeutic strategy, that could be considered in the future for the treatment of ALS and other neurodegenerative diseases.

Materials and methods

Ethics statement

The study protocol was approved by the Ethical Committee of the IRCCS Mondino Foundation (Pavia, Italy). Subjects participating in the study signed an informed consent (Protocol n°375/04 –version 07/01/2004). The study conformed the standards of the Declaration of Helsinki.

Human cell culture and transfection

HeLa cells (CCL-2, American Type Culture Collection [ATCC]) and SH-SY5Y (CRL-2266, American Type Culture Collection [ATCC]) were cultured in Dulbecco’s modified Eagle medium (DMEM, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (S1710-500, Biowest), 1% Penicillin/Streptomycin (L0022-100, Biowest), and 1% L-glutamine (11539876, Gibco). Murine hybridoma cell line ATCC HB-8730 were grown in DMEM supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, and 1500 mg/L sodium bicarbonate (5% CO2). Lymphoblastoid cell lines (LCLs) were harvested with RPMI 1640 (42401018, Gibco) supplemented with 20% of FBS, 1% Penicillin/Streptomycin and 1% L-glutamine.

HeLa cells were transiently transfected using DharmaFect (Dharmacon) according to the manufacturer’s instructions with siC (D-001810-01-05) and siTDP-43 (L-012394-00-0005) and collected after 72h, as described by Dominguez-Sanchez et al. [32]. HeLa cells and SH-SY5Y were stably transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions. HeLa cells were transfected with the following plasmids: pEGFP as control vector expressing GFP (Clontech), and pEGFP-M27, containing the GFP-fused RNaseH1 lacking the first 26 amino acids responsible for its mitochondrial localization cloned into pEGFP [64] that was used to overexpress RNase H1 [60]. All assays were performed 72 h after siRNA transfection or 24 h after plasmid transfection [41].

SH-SY5Y cells were stably transfected using Fugene HD Transfection Reagent (Promega) with C-terminally GFP-tagged TDP-43 WT vector (PS100010 pCMV6-AC-GFP), C-terminally GFP-tagged TDP-43 A382T mutation vector (CW303334 mutated ORF of RC210639 at nt position 1144, changed from G to A, to obtain A382T, inserted in PS100001) and a C-terminally GFP-tagged TDP-43 G294V mutation vector (CW303287 mutated ORF of RG210639 at nt position 881, changed from G to T, to obtain G294V, inserted in PS100010), purchased from OriGene. During the paper the SH-SY5Y are respectively named: SH-SY5Y expressing basal levels of TDP-43, SH-TDP+ overexpressing a GFP-tagged TDP-43 WT form, SH-TDP382 expressing the GFP-tagged p.A382T TDP-43 mutant form and SH-TDP294 expressing the GFP-tagged p.G294V TDP-43 mutant form.

EBV inmortalization of cells from ALS patients

ALS diagnosis was made according to the revised El Escorial Criteria [65]. An healthy volunteer (male of 49 years old), free from any pharmacological treatment and pathology, was recruited at the Transfusion Centre of the IRCCS Policlinico S. Matteo Foundation in Pavia (Italy). Peripheral Blood Mononuclear Cells (PBMCs) from 2 ALS patients (one sporadic ALS patient not harboring mutations in the SOD1, FUS/TLS, TARDBP, C9ORF72 and one ALS patient carrying a homozygous p.A382T TARDBP missense mutation) and 1 control were immortalized with EBV as previously described [46]. PBMCs were isolated from peripheral venous blood by Histopaque-1077 (Sigma-Aldrich) following the manufacturer’s instructions. Briefly, 5 × 106 PBMC cells were re-suspended in RPMI 1640 medium (Sigma-Aldrich), supplemented with 20% fetal bovine serum (FBS; Sigma-Aldrich), 0.3 mg/l L-glutamine, 5% penicillin-streptomycin and cyclosporine A (Sigma-Aldrich). EBV-mix, prepared according to Caputo and collaborators [66], plus RPMI 1640 with cyclosporin A was added to the cells. Cells were incubated at 37°C in a humidified atmosphere with 5% CO2 for 1 week. The medium was then changed and cells were left in incubation until clusters of growing cells appeared.

Immunofluorescence microscopy

For S9.6 IF analysis in HeLa and SH-SY5Y, cells were fixed with cold methanol for 10 minutes at -20°C according the literature [38]. SH-SY5Y cells were treated with 40 U/ml RNaseIII (1 U/μl, Thermo Fisher Scientific) for 30 minutes at 37° using 1X RNase III Reaction Buffer. For γH2AX and FANCD2 IF analysis in HeLa and SH-SY5Y, cells were incubated with a fixation solution (PFA 4%, Triton-X 0,1%) for 10 minutes at room temperature (RT) as previously described [47]. For S9.6 and TDP-43 IF microscopy analysis in LCLs, cells were fixed with two methods: one using formaldehyde and cold acetone and the other using cold methanol.

The following antibodies were used: anti-nucleolin antibody (ab50279, Abcam), S9.6 monoclonal antibody (ATCC HB-8730 hybridoma),anti-TDP-43 antibody (Clone: 6H6E12, Proteintech), anti-γ-H2AX antibody (ab2893, Abcam), anti-FANCD2 antibody (sc-20022, SantaCruz), anti-H3S10P antibody (06–570, Sigma-Aldrich). Antibody signals were detected on a Leica DM6000 microscope equipped with a DFC390 camera (Leica). Data acquisition was performed with LAS AF (Leica). R-loops signal in the nucleoplasm of HeLa and SH-SY5Y cell lines was quantified using ImageJ program by measuring the S9.6 integrated density observed in the DAPI-stained nucleus, subtracting the nucleolar contribution, detected by nucleolin antibody. γH2AX and FANCD2 foci were determined in IF of HeLa and SH-SY5Y cell lines through the relative number of cells containing >10 foci in the nuclei in each condition. In each IF experiment we maintained around 100 counted cells for improving their comparability.

Nuclear area was obtained by measuring the DAPI area using FIJI (ImageJ) [67]

DNA-RNA immunoprecipitation-qPCR

DNA-RNA immunoprecipitation (DRIP) was performed on HeLa and SH-SY5Y cells as already described in literature [58, 68]. The amount of R-loop levels was quantified as a function of input DNA, that for each sample was 10% of the entire amount. Primers used are listed in S1 Table.

Flow cytometry analysis

LCLs from a control (LCL-CTL), a sporadic patient (LCL-SALS) and a A382T TDP-43 mutant patient (LCL-TDP382) were incubated with a vitality dye for 15 minutes (Zombie Violet Fixable Viability Kit, BioLegend). Then, LCLs were incubated for 20 minutes with anti-CD19 antibody for B lymphocytes recognition. Cells were fixed and permeabilized using a kit based on saponin permeabilization (Fixation/Permeabilization Solution Kit, BD) as described [69]. As negative control for R-loop presence, cells were treated with 60 U/ml of ribonuclease H (RNase H, 5.000 units/ml, NEB) using RNase H buffer at 37°C for 1 hour. As negative control for ssRNAs, cells were treated with 100 μg/mL ribonuclease A (RNase A, 10 mg/mL, Thermofisher) in 0.3M NaCl buffer at 37°C for 1 hour. At the end, cells were stained for one hour with conjugated anti-S9.6 antibody (PE/R-Phycoerythrin Conjugation Kit, Abcam) and analysed by flow cytometry (BD FACS Canto II). Logarithmic amplification was used for all channels and FACSDIVA was used for the analysis. Moreover, SH-SY5Y transfection efficiency was analysed through flow-cytometry, detecting cellular GFP signal.

Co-immunoprecipitation studies

Chromatin fraction (Chr fraction) and whole lysate fraction (WL fraction) were extracted from LCL-CTL, LCL-SALS and LCL-TDP382 cells. Cells (107) were resuspended in buffer A (25 mM HEPES, 1.5 mM MgCl2, 10mM KCl, 0.5% NP-40, 1 mM DTT) incubated on ice for 10 minutes to isolate the nuclei and spin at 5000 rpm for 5 min at 4°C. The pellet was resuspended in buffer B (50 μM HEPES pH 7.8, 140 mM NaCl2, 1mM EDTA, 1%Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS) and sonicated for 5 cycles (30 ON/30 OFF) using a Bioruptor Sonicator Brochure—Diagenode. All buffer were supplemented with protease and phosphatase inhibitor. Magnetic beads (Dynabeads, Invitrogen) were conjugated with 10 μg S9.6 antibody and respective murine IgG antibody (sc-2025, Santa Cruz) for 2h at 4°C in agitation, followed by incubation O/N with the samples, recovering 10% prior to incubation. After washes, a part of the samples was eluted using elution buffer (50mM Tris pH 8.0, 1mM EDTA, 1% SDS) at 65°C for 10 minutes twice and resuspended in TE buffer for qPCR analysis. S9.6 immunoprecipitation was evaluated by qPCR in genomic sites enriched for R-loop presence in these cells (NOP58 and ING3) [70]. Input (10% fraction for each sample), S9.6 and IgG were loaded on a 10% SDS-PAGE and co-immunoprecipitation was evaluated by immunoblotting with rabbit anti-TDP-43 (1:1000 dilution), rabbit anti-H3 (1:1000 dilution), rabbit anti-GAPDH (1:10000 dilution). Anti-TDP-43 antibody (Clone: 6H6E12, Proteintech Europe), anti-H3 antibody (ab1791, Abcam), anti-GAPDH antibody (GTX100118, GeneTex), IgG antibody (sc-2025, Santa Cruz) were used.

Quantitative PCR analysis

For real-time (RT)–qPCR analysis, cDNA was synthesized using QuantiTect Reverse Transcription Kit (Qiagen). mRNA expression values of the indicated genes were normalized with mRNA expression of the HPRT housekeeping gene. RT—qPCR was performed with iTaq Universal SYBR Green Supermix (Bio-Rad) and analyzed on 7500 FAST Real-Time PCR system (Applied Biosystems, Carlsbad, CA). Primers are listed in S1 Table.

Viability assays

SH-SY5Y cell viability was assessed by Trypan Blue assay. Briefly, cell suspension was mixed with 0.4% Trypan Blue (Sigma-Aldrich) and counted in three independent experiments with the automated cell counter TC20 (Bio-Rad) to evaluate the percentage of live cells, which was about 75–80%.

Western blot analysis

Total soluble protein samples were extracted in RIPA buffer [50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 12 mM deoxycolic acid, supplemented with 1% protease inhibitor cocktail (PIC)]. Protein-containing supernatants were collected and stored at −80°C. Total soluble protein lysates were loaded onto 8–16% SDS-PAGE gel (Bio-Rad). Samples were transferred to nitrocellulose membrane with Trans-Blot Turbo Transfer System (Bio-Rad). After 5% non-fat dry milk blocking, nitrocellulose membranes were incubated ON at 4°C with the following antibodies: anti-TDP-43 antibody (Clone: 6H6E12, Proteintech), anti-GAPDH antibody (GTX100118, GeneTex). Densitometric analysis of the bands was performed using ImageJ software from three independent experiments.

SH-SY5Y subcellular fractionation was performed according to Pansarasa et al. 2018. Cells were first re-suspended in an ice-cold hypotonic lysis buffer [10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 1% PIC] and incubated on ice. 10% Nonidet NP-40 was added and samples were centrifuged at the maximum speed (16,000 g). Cytoplasmic proteins were collected and stored at −80°C until use. The pellet was re-suspended in an ice-cold hypertonic nuclear extraction buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, 1% PIC) and incubated on ice with agitation. The nuclear extracts were centrifuged at the maximum speed and the nuclear proteins were collected. GFP antibody (Santa Cruz Biotechnology(sc-390394, dilution 1:500), rabbit polyclonal anti-H1 (sc-67324 Santa Cruz Biotechnology; dilution 1:250) and mouse monoclonal anti-lactate dehydrogenase (LDH; sc-133123 Santa Cruz Biotechnology; dilution 1:1000) were used as nuclear and cytoplasm loading controls.

Genome-wide data collection

TDP43 ChIP-seq data was obtained from ENCODE project (www.encodeproject.org) ENCSR033VAZ entry, while DRIPc-seq, DRIP-seq and RNA-seq was gathered from Gene Expression Omnibus under accession number GSE127979 [42]

Genome-wide data downstream analysis

TDP43 ChIP-seq optimal IDR thresholded peaks from 2 biological replicates were retrieved from ENCODE (ENCFF909RMQ). DRIP-seq and DRIPc-seq sequencing reads (GSE127979) were mapped to the human hg38 canonical reference genome using Bowtie2 [71] (Langmead & Salzberg, 2012), while HISAT2 [72] (Kim et al., 2019) was used in the case of RNA-seq. Coverage profiles and metaplot images were obtained using deeptools 2 [73] (Ramírez et al., 2016). MACS2 package [74] (Zhang et al., 2008) was used for peak calling (FDR<0.01; broad region detection with 0.1 cutoff) on DRIPc-seq data. Only regions presenting peaks in both replicates were considered and merged when closer than 5kb using BEDtools [75] (Quinlan & Hall, 2010). In RNA-seq analysis, expressed genes where considered those ones presenting an RPKM average >0.001 from both replicates. ChIPseeker package [76] (Yu etal., 2015) with Ensembl genome annotation release 94 2018 88 [77] (Zerbino et al., 2018) was used for peak annotation. Venn diagrams were obtained using the BioVenn application [78] (Hulsen, T. et al. 2008).

Statistical analysis

Statistical analysis was performed by Student t-test and by One-Way Analysis of Variance (ANOVA test) followed by post hoc comparison as a post-test (GraphPad Prism version 5, San Diego, CA, USA), unless otherwise specified. Values were considered statistically significant when p values were < 0.05.

Supporting information

S1 Fig. R-loop accumulation in siTDP-43 HeLa. Related to Fig 1.

A) Relative TDP43 expression as measured by cDNA-qPCR in control (siC) and TDP-43-depleted (siTDP43) cells. Unpaired t test, two-tailed was done. B) Percentage of cells efficiently transfected (GFP+) overexpressing RNH1. C) Comparative table on S9.6 FC (fold change) between results presented in this study for TDP-43 and others reported for factors involved in R loop homeostasis in HeLa cells. Table shows the relative increase in S9.6 reactivity (S9.6 FC), the cell process in which the factor is involved and the reference. D) DRIP-qPCR at the SNRPN (negative control) gene in siC and siTDP-43-treated HeLa cells gDNA untreated (-) and treated (+) with RNH. Unpaired t test, one-tailed was done. For all cases: Blank, not significant; *, P < 0,05; **, P < 0,01; *** P < 0,001; ****, P < 0,0001.

(TIF)

S2 Fig. Analysis of TDP-43 protein expression in SHSY-TDP382 and SHSY-TDP294 cells. Related to Fig 4.

A) WB against GFP, TDP-43 and GAPDH in SH-SY5Y, SH-TDP+, SH-TDP382 and SH-TDP294. Relative quantifications of TDP43 overexpression rate, measured as GFP-TDP-43/GAPDH, are indicated in the histogram (n = 3). Unpaired t test, two-tailed was done. B) Western blot analysis of nuclear and cytoplasmic fractions of endogeneous TDP-43 and overexpressed TDP-43 forms fused to GFP. Mean+SEM (n = 3) are indicated in the histogram. *, P < 0,05; **, P < 0,01 (Unpaired t test, two-tailed). C) Flow cytometry analysis of TDP-43 overexpression. GFP intensity (GFP-TDP43) for each cell line is shown. Percentage of cell over the threshold are indicated. D) TDP-43 overexpression efficiency as measured by IF. Representative images are showed in the left part, while scatter plot in the right presents TDP43 overexpression rates, as measured by total GFP intensity (GFP-TDP43) in cell population. Median values are indicated. Scale bar: 25μm. Mann-Whitney U test, two-tailed was done. E) IF using TDP-43 and GFP antibodies on SH-SY5Y, SH-TDP+ and SH-TDP382. TDP-43 nuclear abundances for each cell line, measured as total TDP43 intensity, are indicated in the scatter plot. Median values are indicated. Scale bar: 25μm. Mann-Whitney U test, two-tailed was done. F) Nuclear area in SH-SY5Y, SH-TDP+ and SH-TDP382. Mean+SEM (n = 3) are indicated in the histogram. Other details as in Fig 4 and S1 Fig.

(TIF)

S3 Fig. R-loops accumulate in SHSY-TDP382 and SHSY-TDP294 cells. Related to Fig 4.

A) Representative images of S9.6 and nucleolin IFs in SH-SY5Y, SH-TDP+, SH-TDP382 and SH-TDP294. Scale bar: 25μm. B) Percentage of cells efficiently transfected (GFP+) overexpressing RNH1. Unpaired t test, two-tailed was done. C) DRIP-qPCR at the SNRPN (negative control) gene in SH-SY5Y, SH-TDP+ and SH-TDP382 cells gDNA untreated (-) and treated (+) with RNH. Other details as in Fig 4 and S1 Fig.

(TIF)

S4 Fig. R-loops accumulate in p.A382T TDP-43 mutated LCLs. Related to Fig 6.

A) IF of LCL-CTL, LCL-TDP382, LCL-SALS using an anti-TDP-43 antibody and an anti-S9.6 antibody after paraformaldehyde fixation. The scatter plots show the increase of S9.6 signal intensity and the decrease in TDP43 nuclear content in SH-TDP382. Median values are indicated. Scale bar: 10μm. Mann-Whitney U test, two-tailed was done. Nuclear area in SH-SY5Y, SH-TDP+ and SH-TDP382 when fixed in paraformaldehyde (B) and methanol (C) are indicated. Median+SEM are indicated in the histogram. Unpaired t test, two-tailed was done. Other details as in Fig 6 and S1 Fig.

(TIF)

S5 Fig. Cytoplasmic mislocalization of TDP-43 in p.A382T TDP-43 SH-SY5Y. Related to Fig 6.

TDP-43 and TDP-35 strongly interact with S9.6 antibody in TDP-43 mut LCLs WL fraction. A) and B) CoIP between S9.6 and TDP-43 in chromatin of LCL-CTL, LCL-TDP382, LCL-SALS. Input, S9.6 IP and IgG IP of chromatin fraction were loaded on a 10% SDS-PAGE and then immunoblotted with TDP-43, H3 and GAPDH as nuclear and cytosolic loading control. S9.6 binding was tested by qPCR. Quantification of TDP43 relative amounts in chromatin and whole lysate co-IPs are indicated in the histograms. Mean+ SEM are indicated. Unpaired t test, two-tailed was done. Other details as in Fig 6 and S1 Fig.

(TIF)

S1 Table. Oligonucleotides used in this study.

(DOCX)

S1 Data. Source Data: Spreadsheet of source data shown in this study.

(XLSX)

Data Availability

All relevant data are within the manuscript and its Supporting information files and the Spreadsheet of source data.

Funding Statement

Research in C.C’s lab was funded by Fondazione Regionale per la Ricerca Biomedica for TRANS–ALS (Translating Molecular Mechanisms into ALS risk and patient’s well-being: FRRB 2015-0023) and in A.A.’s lab was funded by grants from the European Research Council (ERC2014-AdG669898 TARLOOP), the Spanish Ministry of Economy and Competitiveness (BFU2016-75058-P), and the European Union (FEDER). A.B.F. was supported by a Juan de la Cierva-Formación fellowship (FJCI-2017-34536) from Spanish Ministry of Science and Innovation. M.G. was recipient of a scholarship provided by Erasmus+ Mobility for Traineeships from University of Pavia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Buratti E, Baralle FE (2001) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 276(39):36337–43. 10.1074/jbc.M104236200 [DOI] [PubMed] [Google Scholar]
  • 2.Martinez-Contreras R, Cloutier P, Shkreta L, Fisette JF, Revil T, et al. (2007) hnRNP proteins and splicing control. Adv Exp Med Biol 623:123–147. 10.1007/978-0-387-77374-2_8 [DOI] [PubMed] [Google Scholar]
  • 3.Colombrita C, Onesto E, Megiorni F, Pizzuti A, Baralle FE, et al. (2012) TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their posttranscriptional fate in motoneuron-like cells. J Biol Chem 287(19):15635–47. 10.1074/jbc.M111.333450 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Riva P, Ratti A, Venturin M (2016) The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis. Curr Alzheimer Res 13(11):1219–1231. 10.2174/1567205013666160622112234 [DOI] [PubMed] [Google Scholar]
  • 5.Kawahara Y, Mieda-Sato A (2012) TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A 109(9):3347–52. 10.1073/pnas.1112427109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ayala YM, De Conti L, Avendaño-Vázquez SE, Dhir A, Romano M, et al. (2011) TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 30(2):277–88. 10.1038/emboj.2010.310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316(5828):1160–6. 10.1126/science.1140321 [DOI] [PubMed] [Google Scholar]
  • 8.García-Muse T, Aguilera A (2019) R Loops: From Physiological to Pathological Roles. Cell 179(3):604–618. 10.1016/j.cell.2019.08.055 [DOI] [PubMed] [Google Scholar]
  • 9.Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, et al. (2010) ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 107(30):13318–23. 10.1073/pnas.1008227107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis Nat Rev Neurosci 14(4):248–64. 10.1038/nrn3430 [DOI] [PubMed] [Google Scholar]
  • 11.Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870):1668–72. 10.1126/science.1154584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Su XW, Broach JR, Connor JR, Gerhard GS, Simmons Z (2014) Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve 49(6):786–803. 10.1002/mus.24198 [DOI] [PubMed] [Google Scholar]
  • 13.Corrado L, Ratti A, Gellera C, Buratti E, Castellotti B, et al. (2009) High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Hum Mutat 30(4):688–94. 10.1002/humu.20950 [DOI] [PubMed] [Google Scholar]
  • 14.Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, et al. (2014) Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81(3):536–543. 10.1016/j.neuron.2013.12.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Liu-Yesucevitz L, Lin AY, Ebata A, Boon JY, Reid W, et al. (2014) ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J Neurosci 34(12):4167–74. 10.1523/JNEUROSCI.2350-13.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Santos-Pereira JM, Aguilera A (2015) R loops: new modulators of genome dynamics and function. Nat Rev Genet 16(10):583–97. 10.1038/nrg3961 [DOI] [PubMed] [Google Scholar]
  • 17.Yang C, Tan W, Whittle C, Qiu L, Cao L, et al. (2010) The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS One 5(12):e15878 10.1371/journal.pone.0015878 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ou SH, Wu F, Harrich D, García-Martínez LF, Gaynor RB (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol 69(6):3584–96. 10.1128/JVI.69.6.3584-3596.1995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Huang CC, Bose JK, Majumder P, Lee KH, Huang JT et al. (2014) Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. J. Cell Sci 127(Pt 14):3024–38. 10.1242/jcs.136150 [DOI] [PubMed] [Google Scholar]
  • 20.Xiao S, Sanelli T, Chiang H, Sun Y, Chakrabartty A, et al. (2015) Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol 130(1):49–61. 10.1007/s00401-015-1412-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Guerrero EN, Mitra J, Wang H, Rangaswamy S, Hegde PM, et al. (2019) Amyotrophic lateral sclerosis-associated TDP-43 mutation Q331K prevents nuclear translocation of XRCC4-DNA ligase 4 complex and is linked to genome damage-mediated neuronal apoptosis. Hum Mol Genet 28(5):2459–2476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, et al. (2019) Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci U S A 116(10):4696–4705. 10.1073/pnas.1818415116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hill SJ, Mordes DA, Cameron LA, Neuberg DS, Landini S, et al. (2016) Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proc Natl Acad Sci USA 113(48):E7701–E7709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.D’Alessandro G, d’Adda di Fagagna F (2017) Transcription and DNA damage: holding hands or crossing swords? J Mol Biol 429(21):3215–3229. 10.1016/j.jmb.2016.11.002 [DOI] [PubMed] [Google Scholar]
  • 25.Richard P, Manley JL (2017) R loops and links to human disease. J Mol Biol 429(21):3168–3180. 10.1016/j.jmb.2016.08.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Freudenreich CH (2018) R-loops: targets for nuclease cleavage and repeat instability. Curr Genet 64(4):789–794. 10.1007/s00294-018-0806-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Reddy K, Schmidt MH, Geist JM, Thakkar NP, Panigrahi GB, et al. (2014) Processing of double R-loops in (CAG)•(CTG) and C 9 o r f 72 (GGGGCC)•(GGCCCC) repeats causes instability. Nucleic Acids Res 42(16):10473–87. 10.1093/nar/gku658 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, et al. (2004) DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74(6):1128–35. 10.1086/421054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Groh M, Albulescu LO, Cristini A, Gromak N (2017) Senataxin: genome guardian at the interface of transcription and neurodegeneration. J Mol Biol 429(21):3181–3195. 10.1016/j.jmb.2016.10.021 [DOI] [PubMed] [Google Scholar]
  • 30.Kottemann MC, Smogorzewska A (2013) Fanconi Anemia and the repair of Watson and Crick DNA crosslinks. Nature 493(7432):356–63. 10.1038/nature11863 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bhatia V, Barroso SI, García-Rubio ML, Tumini E, Herrera-Moyano E, et al. (2014) BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature 511(7509):362–5. 10.1038/nature13374 [DOI] [PubMed] [Google Scholar]
  • 32.Ayala YM, Misteli T, Baralle FE (2008) TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A 105(10):3785–9. 10.1073/pnas.0800546105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ginno PA, Lim YW, Lott PL, Korf I, Chédin F (2013) GC skew at the 5’ and 3’ ends of human genes links R-loops formation to epigenetic regulation and transcription termination. Genome Res 23(10):1590–600. 10.1101/gr.158436.113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mersaoui SY, Yu Z, Coulombe Y, Karam M, Busatto FF, et al. (2019) Arginine methylation of the DDX5 helicase RGG/RG motif by PRMT5 regulates resolution of RNA-DNA hybrids. EMBO J 38(15):e100986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Herrera-Moyano E, Mergui X, García-Rubio ML, Barroso S, Aguilera A (2014) The yeast and human FACT chromatin-reorganizing complexes solve R-loop-mediated transcription-replication conflicts. Genes Dev 28(7):735–48. 10.1101/gad.234070.113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Li X, Manley JL (2005) Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122(3):365–78. 10.1016/j.cell.2005.06.008 [DOI] [PubMed] [Google Scholar]
  • 37.Gómez-González B, Aguilera A (2019) Transcription-mediated replication hindrance: a major driver of genome instability. Genes Dev 33(15–16):1008–1026. 10.1101/gad.324517.119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Salas-Armenteros I, Pérez-Calero C, Bayona-Feliu A, Tumini E, Luna R, et al. (2017) Human THO-Sin3A interaction reveals new mechanisms to prevent R-loops that cause genome instability. EMBO J 36(23):3532–3547. 10.15252/embj.201797208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.García-Rubio ML, Pérez-Calero C, Barroso SI, Tumini E, Herrera-Moyano E, et al. (2015) The Fanconi Anemia Pathway Protects Genome Integrity from R-loops. PLoS Genet 11(11):e1005674 10.1371/journal.pgen.1005674 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Schwab RA, Nieminuszczy J, Shah F, Langton J, Lopez Martinez D, et al. (2015) The Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription. Mol Cell 60(3):351–61. 10.1016/j.molcel.2015.09.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Domínguez-Sánchez MS, Barroso S, Gómez-González B, Luna R, Aguilera A (2011) Genome instability and transcription elongation impairment in human cells depleted of THO/TREX. PLoS Genet 7(12):e1002386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Pérez-Calero C, Bayona-Feliu A, Xue X, Barroso SI, Muñoz S, et al. (2020) UAP56/DDX39B is a major cotranscriptional RNA-DNA helicase that unwinds harmful R loops genome-wide. Genes Dev 34(13–14):898–912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–3. [DOI] [PubMed] [Google Scholar]
  • 44.Pesiridis GS, Lee VM, Trojanowski JQ (2009) Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 18(R2):R156–62. 10.1093/hmg/ddp303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Mutihac R, Alegre-Abarrategui J, Gordon D, Farrimond L, Yamasaki-Mann M, et al. (2015) TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca2+ signaling in motor neurons. Neurobiol Dis 75:64–77. 10.1016/j.nbd.2014.12.010 [DOI] [PubMed] [Google Scholar]
  • 46.Pansarasa O, Bordoni M, Drufuca L, Diamanti L, Sproviero D, et al. (2018) Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms. Dis Model Mech 11(3). 10.1242/dmm.031625 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Silva S, Camino LP, Aguilera A (2018) Human mitochondrial degradosome prevents harmful mitochondrial R loops and mitochondrial genome instability. Proc Natl Acad Sci U S A 115(43):11024–11029. 10.1073/pnas.1807258115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Hartono SR, Malapert A, Legros P, Bernard P, Chédin F, et al. (2018) The Affinity of the S9.6 Antibody for Double-Stranded RNAs Impacts the Accurate Mapping of R-Loops in Fission Yeast. J Mol Biol 430(3):272–284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Prasad A, Bharathi A †, Sivalingam V, Girdhar A, Patel BK (2019)Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Frontiers Mol Neurosci 12:25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Scotter EL, Chen HJ, Shaw CE (2015) TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics 12(2):352–63. 10.1007/s13311-015-0338-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhang ZZ, Pannunzio NR, Hsieh CL, Yu K, Lieber MR (2015) Complexities due to single-stranded RNA during antibody detection of genomic RNA-DNA hybrids. BMC Res Notes 8:127 10.1186/s13104-015-1092-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Prpar Mihevc S, Baralle M, Buratti E, Rogelj B (2016) TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Sci Rep 6:33996 10.1038/srep33996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Cestra G, Rossi S, Di Salvio M, Cozzolino M (2017) Control of mRNA Translation in ALS Proteinopathy. Front Mol Neurosci 10:85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Freibaum BD, Chitta RK, High AA, Taylor JP (2010) Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 9(2):1104–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Tank EM, Figueroa-Romero C, Hinder LM, Bedi K, Archbold HC, et al. (2018) Abnormal RNA stability in amyotrophic lateral sclerosis. Nat Commun 9(1):2845 10.1038/s41467-018-05049-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Wood M, Quinet A, Lin Y-L, Davis AA, Pasero P, et al. (2020) TDP-43 dysfunction results in R-loop accumulation and DNA replication defects. J Cell Sci [Epub ahead of print] 10.1242/jcs.244129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Salvi JS, Mekhail K (2015) R-loops highlight the nucleus in ALS. Nucleus 6(1):23–9. 10.1080/19491034.2015.1004952 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Emde A, Eitan C, Liou LL, Libby RT, Rivkin N, et al. (2015) Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J 34(21):2633–51. 10.15252/embj.201490493 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.García-Rubio M, Barroso SI, Aguilera A (2018) Detection of DNA-RNA Hybrids In Vivo. Methods Mol Biol 1672:347–361. 10.1007/978-1-4939-7306-4_24 [DOI] [PubMed] [Google Scholar]
  • 60.Flegel K, Grushko O, Bolin K, Griggs E, Buttitta L (2016) Roles for the Histone Modifying and Exchange Complex NuA4 in Cell Cycle Progression in Drosophila melanogaster. Genetics 203(3):1265–81. 10.1534/genetics.116.188581 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Westman BJ, Lamond AI (2011) A role for SUMOylation in snoRNP biogenesis revealed by quantitative proteomics. Nucleus 2(1):30–7. 10.4161/nucl.2.1.14437 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Che MX, Jiang YJ, Xie YY, Jiang LL, Hu HY (2011) Aggregation of the 35-kDa fragment of TDP-43 causes formation of cytoplasmic inclusions and alteration of RNA processing. FASEB J 25(7):2344–53. 10.1096/fj.10-174482 [DOI] [PubMed] [Google Scholar]
  • 63.Ayala YM, Zago P, D’Ambrogio A, Xu YF, Petrucelli L, et al. (2008) Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 121(Pt 22):3778–85. 10.1242/jcs.038950 [DOI] [PubMed] [Google Scholar]
  • 64.Cerritelli SM, Frolova EG, Feng C, Grinberg A, Love PE, et al. (2003) Failure to produce mitochondrial DNA results in embryonic lethality in RnaseH1 null mice. Mol Cell 11(3):807–15. 10.1016/s1097-2765(03)00088-1 [DOI] [PubMed] [Google Scholar]
  • 65.Brooks BR, Miller RG, Swash M, Munsat TL (2000). El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis; world federation of neurology research group on motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord. 1, 293–299. 10.1080/146608200300079536 [DOI] [PubMed] [Google Scholar]
  • 66.Caputo J.L, Thompson A, McClintock P, Reid YA, Hay RJ (1991). An effective method for establishing human B lymphoblastic cell lines using Epstein-barr virus. J. Tiss. Cult. Meth. 13, 39–44. [Google Scholar]
  • 67.Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–82. 10.1038/nmeth.2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sanz LA, Chédin F (2019) High-resolution, strand-specific R-loops mapping via S9.6-based DNA-RNA immunoprecipitation and high-throughput sequencing. Nat Protoc 14(6):1734–1755. 10.1038/s41596-019-0159-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Schauer U, Jung T, Krug N, Frew A (1996) Measurement of intracellular cytokines. Immunol Today 17(7):305–6. 10.1016/0167-5699(96)30020-0 [DOI] [PubMed] [Google Scholar]
  • 70.Halász L, Karányi Z, Boros-Oláh B, Kuik-Rózsa T, Sipos É, et al. (2017) RNA-DNA Hybrid (R-loops) Immunoprecipitation Mapping: An Analytical Workflow to Evaluate Inherent Biases. Genome Res 27(6):1063–1073. 10.1101/gr.219394.116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2 (2012) Nat Methods 9(4):357–9. 10.1038/nmeth.1923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Kim D, Paggi JM, Park C, Bennett C, Salzberg SL (2019) Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 37(8):907–915. 10.1038/s41587-019-0201-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, et al. (2016) deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res 44(W1):W160–5. 10.1093/nar/gkw257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137 10.1186/gb-2008-9-9-r137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26(6):841–2. 10.1093/bioinformatics/btq033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Yu G, Wang LG, He QY (2015) ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31(14):2382–3. 10.1093/bioinformatics/btv145 [DOI] [PubMed] [Google Scholar]
  • 77.Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, et al. (2018) Emsembl 2018. Nucleic Acids Res 46(D1):D754–D761. 10.1093/nar/gkx1098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Hulsen T, de Vlieg J, Alkema W (2008) BioVenn—a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics 9:488 10.1186/1471-2164-9-488 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Gregory S Barsh, Dmitry A Gordenin

17 Jun 2020

Dear Dr Aguilera,

Thank you very much for submitting your Research Article entitled 'TDP-43 deficiency links Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. While Reviewer 2 was generally positive, Reviewers 1 and 3 found that the presented data are not sufficient to support the manuscript's conclusions.  Both reviewers indicated and Reviewer 3 specifically suggested using additional experimental approaches to validate your conclusions.  Also, please note a request of Reviewer 1 to include source data underlying graphical display items, which is currently a PLOS Minimal Data Set Definition requirement.  (see below the link and clarification of data availability policy).

Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our guidelines.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Dmitry A. Gordenin

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: In the manuscript “TDP-43 deficiency links Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated damage,” Giannini and co-authors explore the role of TDP-43 in the maintenance of genome integrity and try to dissect the mechanism of the neurodegenerative pathogenesis caused by the mutated version of the protein. They test the hypothesis that TDP-43 prevents the accumulation of DSB-inducing, deleterious R-loops and claim that an R-loop-dependent increase in DSB foci and Fanconi Anemia repair centers is caused by mis-localization of the mutated protein in transfected neuronal cells and in cell lines from ALS patients. Without a doubt, the findings reported in the manuscript are significant and worth further investigation; however, the conclusions drawn from the data are not sufficiently substantiated.

Major concerns.

1. The depletion of TDP-43 in HeLa cells by siRNA leads to a minor increase in S9.6 signal intensity (Figure 1A). Even though the increase is statistically significant, the biological relevance of such an increase is unclear without comparison to the changes in intensity after depletion of the known protein involved in R-loop processing. This concern is exacerbated by the absence of an increase in DRIPqPCR product for the APOE gene in siTDP-43 treated cells (Figure 1B). Taking into account this marginal effect on R-loop formation on the one hand and the multiple functions of TDP-43 in mRNA processing and its interaction with DNA on the other, the increase in gammaH2AX and FANCD2 foci (Figure 2) could reflect consequences of TDP-43 depletion that are unrelated to R-loop processing. The decrease in foci in cells expressing RNaseH could also be an indirect consequence of the protein depletion.

2. The statement from the abstract, “we prove that mislocalization of mutated TDP-43 (A382T) in transfected neuronal SH-SY5Y and lymphoblastoid cell lines (LCLs) from an ALS patient cause R-loop accumulation, and R loop-dependent increased DSBs and Fanconi Anemia repair centers” is misleading. Mis-localization of both proteins - mutant and wild type - leads to an increase in S9.6 intensity (Figure 3A), and the difference in S9.6 signal intensity between the cells with mutant and wild type proteins is not significant. It is well documented that overexpression of proteins can cause their mis-localization and misfunction. So, “significantly decreased” nuclear localization of the mutant protein in SHSY-TDP382 cells (decrease of less than 15%) compared to wild type SHSY-TDP+ cells (Supplementary Figure 1) can result from (slightly) different expression levels of each of the proteins in the corresponding cell lines. In other words, the somewhat increased deleterious consequences of expression of the mutant allele could be caused by a higher level of overexpression of the mutant protein, compared to the wild type allele, rather than the presence of a missense mutation.

Unless the levels of TDP+ and TDP382 proteins are measured and found similar, the “mutation” effects could be attributed to the differential expression levels of TDP-43 alleles in the cells.

3. The same critique applies to the experiments with the lymphoblastoid cells from the patients.

4. The data in Figure 6 are neither quantified nor normalized. The quantity of the loading control proteins varies from lane to lane. Also, it is unclear how many times the experiment has been performed, so the discussion of the results of this experiment is mere speculation.

5. In Figure 3A, the increase in S9.6 signal in the cells with overexpression of TDP+ cannot be attributed to R-loop formation because overexpression of RNaseH does not decrease the signal. Nevertheless, the authors make the following conclusion: “Therefore, we conclude that mislocalisation of TDP-43 also causes R-loop accumulation “(page 8). This statement contradicts the data. It is unclear whether the levels of overexpression of RNaseH were monitored during the experiments in different cell lines. One explanation of these data could be that the expression of RNaseH in the specific cell line was different (lower) from the others.

6. Throughout the study, the only assay utilized for providing evidence for DNA damage or activation of DNA damage response is the detection of DNA repair foci. Additional, independent tests (such as measurement of homologous recombination or non-homologous end-joining in reporter systems, evaluation of checkpoint activation, assessment of sensitivity to DNA damaging agents) are necessary to address physiological consequences of TDP43 malfunctioning.

Minor concerns.

1. There is no description of how overexpression of RNaseH is achieved in Figures 1-5. Reference #33, used for an explanation (Ginno et al., 2013), does not provide relevant information.

2. Since in Figures 3A and Supplemental Figure 1, the data presented as “signal per nucleus” and the differences in these signals are minor, it seems to be important to make sure that the area (size) of the nuclei are similar among cells transfected with different constructs.

3. Flow cytometry plots in Figures 5B and C do not include the plot of S9.6 signal for the LCL-SALS cells (cells from sporadic ALS patient), making the data representation skewed.

Reviewer #2: In this manuscript, Gianini et al. have investigated in detail the role played by TDP-43 in the generation of R-loops and RNA:DNA hybrids in neuronal and non-neuronal cell lines. In general, the manuscript contains interesting data for the field and several novel observations that contribute to a better understanding of the protein in disease. A few required additions and clarifications are as follows:

-The title “TDP-43 deficiency links Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage” does not seem appropriate since the manuscript principally focuses on a disease-associated mutation, A382T. Therefore, it might be better to change it in “TDP-43 mutation links Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage”.

- The order followed in the abstract is not the one respected in the results (ie. in the abstract the authors first write about mislocalization of mutated TDP-43 (A382T) in transfected neuronal SH-SY5Y and lymphoblastoid cell lines (LCLs) from an ALS patient cause R-loop accumulation and then a non-neuronal model of HeLa cells depleted of TDP-43. However, in the results they present first the depletion of TDP-43 in Hela cells and then the transfection of mutated TDP-43 in SHSY-5Y. Please be consistent in the order of the text.

- In the work the authors used silenced TDP-43 in Hela cells but transfected mutated TDP-43 in SHSY-5Y. Please explain better the choice of the two cell lines and how they are connected.

- In the LCLs mutated in TDP-43 the authors observe an increase of R-loops compared to CTL and SALS LCLs. RNAse H could revert partially the S9.6 increase signal. How can this partial decrease be explained?

- Experiments were run in SHSY5Y and in LCL carrying only one mutation A382T. It might be interesting to carry out at least part of the reported experiments in SHSY-5Y cells overexpressing TDP-43 with another mutation. These data would confirm whether the readouts observed with this mutation are specific or not.

Reviewer #3: The paper by Gianini et al focuses on understanding how deficiency of TDP-43 observed in ALS is connected with R-loop homeostasis and R-loop mediated DNA damage. Previous work from Livinsgton lab has demonstrated that TDP43 is involved in prevention/repair of transcription-associated DNA damage through R-loop-related mechanisms in neuronal cells (Hill et al PNAS 2016), therefore the novelty of this paper is partially compromised by this publication. One interesting aspect which the authors were trying to pursue is to uncover if TDP-43-disease-associated mutations which result in re-localisation of usually nuclear TDP43 to the cytoplasm has any effect on R-loop-mediated DNA damage. This is certainly an interesting question worth addressing. The authors pursued these questions in HeLa cells (where TDP43 is depleted, Fig 1-2), neuroblastoma cells (where TDP-43 wt or mutant is over-expressed, Fig 3-4) and lyphoblastoid cells (with patient mutations in endogenous TDP43, Fig 5-6). Using these model systems, the authors have shown that TDP43 deficiency results in accumulation of R-loops (by IF and DRIP-qPCR), DNA damage (γH2AX) and Fanconi Anemia repair centers. Unfortunately, the authors have not managed to take these initial findings, some of which were already reported in Hill et al PNAS 2016. (i.e. R-loop and DNA damage increase), into subsequent mechanistic investigations. For the reasons of the quality and amount of data presented in this paper, at this current stage the paper is not suitable for publication in PLoS Genetics.

Major comments:

1. The amount of data presented in this paper is minimal and not of a good quality which overall does not give me the confidence of the general paper conclusions. In particular the conclusions drawn from S9.6 IF analysis are rather ‘pushed’ and not visible from the images presented. For example, Fig 1A does not have a clear nuclear signal in any of the images shown (only nucleolar signal is visible). The differences between quantified signals are very small and represent only a background signal, in my opinion). The RNase H over-expression does not result in any visible change of the signal on the images. The positive controls (known factor which up-regulates R-loop level) are missing. The authors have not quantified nucleolar signal (are there any changes there?), though they have chosen to study gene encoding ribosomal protein in their DRIP analysis (see below).

2. It is surprising to me that the only gene which shows statistically significant accumulation of R-loops is RPL13A, which is a ribosomal protein. I would like to see more comprehensive analysis of R-loop increase by DRIP-qPCR. Other multiple genes of different categories should be tested in different model systems.

3. Experiments in Fig 3-4 are carried out with neuroblastoma cells, where TDP-43 Wt or mutant (TDP382) are expressed on the endogenous background. The authors need to characterise this system a bit better, since the imaging in Fig S1 is not sufficient. They need to present Westen blot showing the level of expression of endogenous and over-expressed proteins in different cellular fractions (i.e. nucleus, cytoplasm) in all three cell lines. What is the level of endogenous protein contribution to all results observed? The authors have not really explained why do we observe a significant decrease of nuclear signal for TDP43 WT cells compared to control cells? These data are important for further interpretation of IF and DRIP results. All these experiments should have been performed on the background of depleted endogenous TDP-43 protein to have a clear interpretation.

4. The authors have carried out IF in Lymphoblast cells from patients with TDP43 and ALS mutations. Similar to my comments for Figures 1A and 3A, the IF data are not convincing and show extremely small changes between cell lines studied. These cells derived from different people and are subject to patient –to patient genetic variation. Since the data are showing rather small changes, the authors should use multiple cell lines representing each category. Possibly using alternative approaches such as slot blot may provide more quantitative data than IF.

5. Figure 6 contains results of S9.6 IP experiments in lymphoblast cells. The authors propose that they observe less TDP43 interaction with R-loops when TDP43 is mutated. This is not visible from the protein gel presented, and as far as I am concern represents a wishful thinking of the authors and not the result of a given experiment. There is absolutely minimal pull-down observed with TDP-43 in the nucleus, and mainly there is a pull down of TDP-35 which should be really cytoplasmic, and not in the chromatin fraction? Clearly these TDP-35 fragments are also IPed in the WT conditions – why is this happening? This experiment lacks RNase H control to show that interaction between TDP43 and R-loops is specific. Comments regarding stronger pull-down of TDP35 in TDP43 mutant in cytoplasm are not really substantiated since it is clear that this sample is over-loaded on the gel as can be seen from H3 and GAPDH westerns.

Minor comments:

1. On page 9 first paragraph, the authors say that ‘TDP-43 mutation causes an increase in DNA breaks derived from R-loop accumulation that promotes transcription-replication collisions..’ . I think that this is an over-statement since it has not really been tested if accumulation of R-loops following TDP-43 depletion results in transcription-replication collisions.

2. The authors need to explain why SNRPN gene does not have DRIP signal – it is not expressed?

3. All the data in this paper can be grouped in 2-3 figures max (one figure for each cell model used).

4. The paper would benefit from additional English editing (i.e. - ‘significant’ on pages 6 and 11 should be spelled correctly..etc)

5. Concluding model demonstrating TDP43 role in disease and R-loop biology would be helpful.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: No: The numerical data underlying graphs are not provided in spreadsheet form.

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Decision Letter 1

Gregory S Barsh, Dmitry A Gordenin

2 Nov 2020

* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. *

Dear Dr Aguilera,

Thank you very much for submitting your Research Article entitled 'TDP-43 mutations link Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition we ask that you:

1) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.  Please also note that one of reviewers stated that the revision should include all source data, i.e., numerical data underlying graphs or summary statistics are included with the submission.  This request goes along with PLOS data availability policy.  Should your manuscript is accepted for publication, the most helpful to future readers would be if the specific sections of supplemental tables or separate supplementary tables containing source data for the display item would be specified in the corresponding figure legend or table footnotes.

2) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our archive. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Dmitry A. Gordenin, Ph.D.

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The revised manuscript by Gianini et al., “TDP-43 deficiency links Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated damage,” is much improved compared to the original version.

Most of the issues that caused concerns in the paper’s previous version regarding data interpretation and appropriate controls are addressed and resolved in the updated manuscript.

The added comparison of the consequences of TDP-43 depletion on R-loop formation (reported as changes in S9.6 fluorescence intensity) to the measurements already published in the studies of the contribution of proteins directly involved in R-loop processing (S1C Fig), as well as DRIP-seq of additional R-loop - prone targets, allows appreciation of the biological relevance of relatively minor changes in fluorescence levels.

The data from the new experiments involving treatment of the cells with RNAse III for the removal of dsRNA (Figure 4A) eliminate the ambiguity of the results reported in the first version of the manuscript and validate the statement, “we prove that mislocalization of mutated TDP-43 (A382T) in transfected neuronal SH-SY5Y and lymphoblastoid cell lines (LCLs) from an ALS patient cause R-loop accumulation…”

Measurements of the expression levels of the wild type and mutant constructs (reported in S2A and C Figures) strengthen the conclusion that indeed mislocalization, rather than an increased level of the mutant protein, causes accumulation of R-loops.

Several points still require the authors’ attention.

1. Even though the new genome-wide analysis of TDP-43 localization (Figure 3) does not provide direct evidence of the contribution of TDP-43 to R-loop processing but instead suggests that TDP-43 binds to highly expressed loci in DNA, these data offer new insights into TDP-43 functions. Nevertheless, the statement “…TDP-43 RBP controls transcription at expressed genes that are prone to accumulate R loops...” is not substantiated by the data and should be toned down.

2. Since statistically significant “reduction in nuclear fraction” of endogenous TDP-43 was NOT observed either following expression of SH-TDP+, or SH-TDP382, it is formally incorrect to attribute an absence of a reduction in SH-TDP294 to any phenotype (S2BFig). (“In the case of SH-TDP294, a reduction in the nuclear fraction was not observed in the western blot, therefore implying that protein dysfunction can be causative of the phenotype.”, p. 8).

3. The model in Figure 6C must be adjusted to accommodate the data showing that a decrease (compared to control) in nuclear localization of overexpressed wild type TDP-43 (2SE Figure, SH-TDP+ vs. SH-SY5Y) does not cause an increase in S9.6 intensity (Figure 4A).

4. The spreadsheets with the raw data reflected in graphs and figures are not provided.

Reviewer #2: The authors have provided several new data and have addressed in detail most of the queries raised by reviewers.

Reviewer #3: The authors have made an effort to improve this manuscript including additional genes for DRIP-qPCR analysis (as requested in my comment 2) and some modest visual improvement for S9.6 IF.

Related to previous comment 1:

To address my concern related to small changes in IF signal in the nucleus associated with Pol II genes, the authors introduced genomic data from publicly available Encode and previously published data, showing a correlation between TDP-43 binding and R-loops in expressed genes under physiological conditions in K562 cells (fig 3). Based on these datasets TDP-43 is mainly enriched at the 5’end /TSS of the expressed genes, while R-loops can be found in multiple locations (as shown by the DRIP-qPCR examples in the paper, where TDP-43-sensitive R-loops are enriched across various genomic locations). However, these new genomic data in Fig 3 does not clarify what happens with this correlation when TDP-43 is depleted? Do R-loops accumulate only at the locations where TDP-43 is bound which would support the direct effects of TDP-43 on the regulation of these R-loops? The authors have not demonstrated if they see a specific enrichment of TDP-43 binding at R-loops of their tested genes by DRIP-qPCR supporting the specificity and direct effects of TDP-43 on these R-loops.

Related to previous comment 4:

Unfortunately the authors have failed to introduce additional patient cell lines to verify the effects of R-loop accumulation in patients with different genetic backgrounds. Therefore, in my opinion, providing a direct evidence that TDP-43 binds at the regions of R-loops affected following its depletion (as discussed above) is crucial.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: No: The data underlying the figures are not provided

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Attachment

Submitted filename: Revised manuscript by Gianini et al.docx

Decision Letter 2

Gregory S Barsh, Dmitry A Gordenin

8 Nov 2020

Dear Dr Aguilera,

We are pleased to inform you that your manuscript entitled "TDP-43 mutations link Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Dmitry A. Gordenin, Ph.D.

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: 

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-20-00749R2

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

Gregory S Barsh, Dmitry A Gordenin

28 Nov 2020

PGENETICS-D-20-00749R2

TDP-43 mutations link Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage

Dear Dr Aguilera,

We are pleased to inform you that your manuscript entitled "TDP-43 mutations link Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Nicola Davies

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. R-loop accumulation in siTDP-43 HeLa. Related to Fig 1.

    A) Relative TDP43 expression as measured by cDNA-qPCR in control (siC) and TDP-43-depleted (siTDP43) cells. Unpaired t test, two-tailed was done. B) Percentage of cells efficiently transfected (GFP+) overexpressing RNH1. C) Comparative table on S9.6 FC (fold change) between results presented in this study for TDP-43 and others reported for factors involved in R loop homeostasis in HeLa cells. Table shows the relative increase in S9.6 reactivity (S9.6 FC), the cell process in which the factor is involved and the reference. D) DRIP-qPCR at the SNRPN (negative control) gene in siC and siTDP-43-treated HeLa cells gDNA untreated (-) and treated (+) with RNH. Unpaired t test, one-tailed was done. For all cases: Blank, not significant; *, P < 0,05; **, P < 0,01; *** P < 0,001; ****, P < 0,0001.

    (TIF)

    S2 Fig. Analysis of TDP-43 protein expression in SHSY-TDP382 and SHSY-TDP294 cells. Related to Fig 4.

    A) WB against GFP, TDP-43 and GAPDH in SH-SY5Y, SH-TDP+, SH-TDP382 and SH-TDP294. Relative quantifications of TDP43 overexpression rate, measured as GFP-TDP-43/GAPDH, are indicated in the histogram (n = 3). Unpaired t test, two-tailed was done. B) Western blot analysis of nuclear and cytoplasmic fractions of endogeneous TDP-43 and overexpressed TDP-43 forms fused to GFP. Mean+SEM (n = 3) are indicated in the histogram. *, P < 0,05; **, P < 0,01 (Unpaired t test, two-tailed). C) Flow cytometry analysis of TDP-43 overexpression. GFP intensity (GFP-TDP43) for each cell line is shown. Percentage of cell over the threshold are indicated. D) TDP-43 overexpression efficiency as measured by IF. Representative images are showed in the left part, while scatter plot in the right presents TDP43 overexpression rates, as measured by total GFP intensity (GFP-TDP43) in cell population. Median values are indicated. Scale bar: 25μm. Mann-Whitney U test, two-tailed was done. E) IF using TDP-43 and GFP antibodies on SH-SY5Y, SH-TDP+ and SH-TDP382. TDP-43 nuclear abundances for each cell line, measured as total TDP43 intensity, are indicated in the scatter plot. Median values are indicated. Scale bar: 25μm. Mann-Whitney U test, two-tailed was done. F) Nuclear area in SH-SY5Y, SH-TDP+ and SH-TDP382. Mean+SEM (n = 3) are indicated in the histogram. Other details as in Fig 4 and S1 Fig.

    (TIF)

    S3 Fig. R-loops accumulate in SHSY-TDP382 and SHSY-TDP294 cells. Related to Fig 4.

    A) Representative images of S9.6 and nucleolin IFs in SH-SY5Y, SH-TDP+, SH-TDP382 and SH-TDP294. Scale bar: 25μm. B) Percentage of cells efficiently transfected (GFP+) overexpressing RNH1. Unpaired t test, two-tailed was done. C) DRIP-qPCR at the SNRPN (negative control) gene in SH-SY5Y, SH-TDP+ and SH-TDP382 cells gDNA untreated (-) and treated (+) with RNH. Other details as in Fig 4 and S1 Fig.

    (TIF)

    S4 Fig. R-loops accumulate in p.A382T TDP-43 mutated LCLs. Related to Fig 6.

    A) IF of LCL-CTL, LCL-TDP382, LCL-SALS using an anti-TDP-43 antibody and an anti-S9.6 antibody after paraformaldehyde fixation. The scatter plots show the increase of S9.6 signal intensity and the decrease in TDP43 nuclear content in SH-TDP382. Median values are indicated. Scale bar: 10μm. Mann-Whitney U test, two-tailed was done. Nuclear area in SH-SY5Y, SH-TDP+ and SH-TDP382 when fixed in paraformaldehyde (B) and methanol (C) are indicated. Median+SEM are indicated in the histogram. Unpaired t test, two-tailed was done. Other details as in Fig 6 and S1 Fig.

    (TIF)

    S5 Fig. Cytoplasmic mislocalization of TDP-43 in p.A382T TDP-43 SH-SY5Y. Related to Fig 6.

    TDP-43 and TDP-35 strongly interact with S9.6 antibody in TDP-43 mut LCLs WL fraction. A) and B) CoIP between S9.6 and TDP-43 in chromatin of LCL-CTL, LCL-TDP382, LCL-SALS. Input, S9.6 IP and IgG IP of chromatin fraction were loaded on a 10% SDS-PAGE and then immunoblotted with TDP-43, H3 and GAPDH as nuclear and cytosolic loading control. S9.6 binding was tested by qPCR. Quantification of TDP43 relative amounts in chromatin and whole lysate co-IPs are indicated in the histograms. Mean+ SEM are indicated. Unpaired t test, two-tailed was done. Other details as in Fig 6 and S1 Fig.

    (TIF)

    S1 Table. Oligonucleotides used in this study.

    (DOCX)

    S1 Data. Source Data: Spreadsheet of source data shown in this study.

    (XLSX)

    Attachment

    Submitted filename: PLoS Genet_Rebuttal.docx

    Attachment

    Submitted filename: Revised manuscript by Gianini et al.docx

    Attachment

    Submitted filename: Giannini et al_Response to reviewers_R2.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files and the Spreadsheet of source data.


    Articles from PLoS Genetics are provided here courtesy of PLOS

    RESOURCES